Britton Jimenez (BJ), SVP, Sales and Marketing at Codexis, tells Dr Kevin Robinson (KSR) that early process understanding, meaningful monitoring and simpler technologies are key to keeping complex therapies predictable and consistent at scale.
KSR: As medicines and manufacturing processes become more complex, what are the biggest challenges when moving from development into scalable production?
BJ: Pharmaceutical innovation is pushing manufacturing into increasingly complex territory. More sophisticated small molecules, advanced biologics and nucleic acid therapeutics are creating possibilities that would have been difficult to imagine a decade ago.
But one message coming through clearly from CPHI Milan 2026 is that scientific complexity cannot simply be passed downstream as a manufacturing issue.
Formulation, scale-up, quality and supply increasingly need to be considered together rather than as separate activities.
The scale-up challenge is increasingly one of process understanding. Methods that perform successfully during development do not always behave predictably as they move into larger equipment, different facilities or commercial production.
